Burning Rock Biotech
Update in progressBNR (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDiagnostics & Research
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in China and the United States, across Central Laboratory, In-Hospital, and Pharma R&D services. It provides NGS-based tissue and liquid biopsy tests to guide therapy and prognosis for multiple cancers. Key products include OncoScreen Focus (NSCLC), OncoScreen Plus (pan-cancer tissue), OncoCompass Plus (liquid biopsy), OncoCompass Target (ctDNA NSCLC), and ColonCore (MSI and GI mutations). Founded 2014, Guangzhou.
Company score
- Sentiment
- 0.53
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.18
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.31
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!